HB 2612 requires insurance companies selling long-term care insurance in the state to submit premium rate proposals to the Department of Commerce and Insurance (DCI) for prior approval before implementing them, effective August 28, 2026. Insurers cannot charge new or changed premiums without DCI's written approval, and DCI must act within 90 days (or the rate is automatically approved). DCI may disapprove rates if they are unreasonable, unfairly discriminatory, excessive, or based on unrealistic assumptions, providing written reasons for rejection. The bill also mandates public hearings or comment periods for rate filings and gives DCI authority to later revise approved rates.
HB 2724 requires most Missouri health insurance plans covering pregnancy to also cover infertility diagnosis and treatment starting August 28, 2026. It mandates coverage for specific procedures like IVF, embryo transfer, artificial insemination, and fertility preservation during cancer treatment (e.g., chemotherapy). The law limits IVF coverage to cases where less expensive treatments have failed, caps coverage at four egg retrieval cycles (with exceptions for live births), and exempts religiously affiliated plans that oppose these treatments based on faith. This directly affects employers offering health insurance to 25+ employees in Missouri.
Based solely on the provided context, a detailed summary cannot be generated. The bill title and abstract only state the general topic ("insurance coverage for treatment of obesity in certain persons") without specifying who "certain persons" are, what treatments are covered, or the exact requirements for insurers. No key mechanisms, provisions, or concrete policy changes are described in the available information. The bill is in its very early stage (first reading on 2026-01-29), and no further details about its content or scope are provided.
HB 2726 requires Missouri health insurance plans (effective January 1, 2027) to cover a prescribed drug without forcing patients to switch to an alternative drug, unless a patient's doctor provides written approval stating the switch is medically necessary. This directly affects patients prescribed specific medications and health insurers offering plans in Missouri. The bill prevents insurers from mandating drug substitutions solely for cost reasons, ensuring coverage for the doctor-recommended drug. Exceptions include existing step therapy protocols and interchangeable biological products, as specified in related laws.
SB 1569 requires health insurance plans to cover treatment for certain menopause-related conditions, directly affecting insured individuals experiencing these health issues. The bill establishes new insurance coverage mandates, ensuring that specific treatments are included in standard coverage without additional out-of-pocket costs for patients. This policy change applies to all health insurance providers offering coverage within the state, aiming to improve access to medically necessary menopause care. The bill is currently under review by the Senate Insurance and Banking Committee.
HB 2642 requires health insurance plans to cover nonopioid medications for acute pain without barriers, directly affecting people with health insurance (enrollees) and the plans themselves. The law prohibits plans from denying coverage for nonopioid drugs in favor of opioids, forcing patients to try opioids first, or charging higher costs for nonopioid options compared to opioids. It applies only to acute pain (expected to last 30 days or less) and takes effect for plans renewed or issued after January 1, 2027. The bill does not change provider prescribing practices but mandates equal treatment for nonopioid alternatives under insurance coverage.
HB 3088 bans specific clauses in health care provider network contracts that limit patient choice and transparency. It prohibits providers from including "anti-steering" (restricting patient referrals to specific providers), "anti-tiering" (blocking tiered pricing systems), "gag" (hiding price/quality data), or "most-favored-nation" (forcing equal rates across insurers) clauses. Any existing contract with these clauses becomes void, while insurers must act in patients' best interests when designing networks. This directly affects health care providers, insurers, and the patients covered by health benefit plans.
SB 1571 modifies insurance coverage requirements for orthotic, prosthetic, and assistive devices. It directly affects individuals who rely on these medical devices, such as people with mobility impairments or chronic conditions. The bill changes existing provisions to clarify or adjust how health insurers must cover these specific items. This legislation is currently in committee review after its initial reading in January 2026.
HB 3059 requires health insurance plans in Missouri to cover prescription drugs for advanced, metastatic cancer and related symptoms (like treatment side effects) without first demanding that patients try and fail other drugs. It directly affects cancer patients enrolled in health benefit plans, including MO HealthNet (Missouri's Medicaid program), by removing barriers to accessing necessary medications. The bill specifies coverage must apply to FDA-approved drugs that align with evidence-based medical guidelines and best practices for treating advanced cancer. This change ensures patients aren't forced to undergo ineffective treatments or provide proof of prior failures before receiving covered care.
HB 3010 sets strict time limits for health insurance companies on prior authorization decisions for medical services. It requires insurers to make initial review decisions within 36 hours, provide phone notifications within 24 hours for both approvals and denials, and send written confirmation within 1-2 working days. The bill specifically extends approval validity to 12 months for chronic conditions (like cancer treatment) and prohibits billing patients for services with valid prior authorization, except for standard cost-sharing. These rules apply directly to health insurance companies, healthcare providers, and patients enrolled in health benefit plans.
